HH-2710

N/A

Report date: 2023/04/13 20:00:29
NME

Base Information

Drug NameHH-2710
Drug Alias NameHH-2710
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionExtracellular-signal-regulated kinase1 inhibitorsExtracellular-signal-regulated kinase 2 inhibitors
TargetsExtracellular-signal-regulated kinase1Extracellular-signal-regulated kinase 2
Therapy Area/IndicationsErdheim-Chester DiseaseCarcinoma, Non-Small-Cell LungMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesShangHai HaiHe Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesHaihe Biopharma (HK) LtdShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
Active IndicationsN/A
Inactive IndicationsErdheim-Chester DiseaseCarcinoma, Non-Small-Cell LungMelanoma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A